TSS
FOLD

Two Sigma Securities’s Amicus Therapeutics FOLD Stock Holding History

Two Sigma Securities’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,200
Closed -$220K – 2190
2019
Q1 		$220K Buy
+16,200
New +$198K ﹤0.01% 1415

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Two Sigma Securities's FOLD Position: Q1 2026 in Review

Two Sigma Securities opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 11,955 shares worth $173K. The stake represents 0.02% of the portfolio and ranks #1078 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in FOLD as recently as Q3 2025.

Two Sigma Securities first reported a position in FOLD in Q2 2017 and has held it in 6 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Two Sigma Securities held 11,955 shares of Amicus Therapeutics worth $173K as of Q1 2026.
  • Amicus Therapeutics was a new Two Sigma Securities position in Q1 2026.
  • Amicus Therapeutics made up 0.02% of Two Sigma Securities's portfolio in Q1 2026, its #1078 holding.
  • Two Sigma Securities first reported a position in Amicus Therapeutics in Q2 2017 and has held it in 6 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.